
PFE
Pfizer Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
25.540
Open
25.390
VWAP
25.35
Vol
25.67M
Mkt Cap
144.12B
Low
25.260
Amount
650.91M
EV/EBITDA(TTM)
7.94
Total Shares
5.67B
EV
189.27B
EV/OCF(TTM)
13.53
P/S(TTM)
2.32
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
17.92B
+0.87%
0.692
+9.92%
17.14B
-3.19%
0.847
-20.14%
13.46B
+1.34%
0.568
-5.31%
Estimates Revision
The market is revising Downward the revenue expectations for Pfizer Inc. (PFE) for FY2025, with the revenue forecasts being adjusted by -0.59% over the past three months. During the same period, the stock price has changed by 10.60%.
Revenue Estimates for FY2025
Revise Downward

-0.59%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+1.71%
In Past 3 Month
Stock Price
Go Up

+10.60%
In Past 3 Month
18 Analyst Rating

11.95% Upside
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 28.38 USD with a low forecast of 24.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
13 Hold
0 Sell
Moderate Buy

11.95% Upside
Current: 25.350

Low
24.00
Averages
28.38
High
33.00

11.95% Upside
Current: 25.350

Low
24.00
Averages
28.38
High
33.00
BMO Capital
Outperform
to
NULL
downgrade
$26 -> $15
2025-05-13
Reason
BMO Capital
Price Target
$26 -> $15
2025-05-13
downgrade
Outperform
to
NULL
Reason
BMO Capital lowered the firm's price target on Terns Pharmaceuticals to $15 from $26 and keeps an Outperform rating on the shares. The company's TERN-701 dose expansion updates are positive with data to come in Q4, and the recent patent correspondences with USPTO indicate reviewers of '601 have removed double patenting rejections in reference to Pfizer's (PFE) danuglipron, the analyst tells investors in a research note. BMO adds however that its price target is reduced as the recent macro headwinds have increased its capital cost assumptions.
Cantor Fitzgerald
Carter Gould
Hold
Initiates
$24
2025-04-22
Reason
Cantor Fitzgerald
Carter Gould
Price Target
$24
2025-04-22
Initiates
Hold
Reason
UBS
Trung Huynh
Hold
Maintains
$28 → $24
2025-04-08
Reason
UBS
Trung Huynh
Price Target
$28 → $24
2025-04-08
Maintains
Hold
Reason
UBS analyst Trung Huynh lowered the firm's price target on Pfizer to $24 from $28 and keeps a Neutral rating on the shares. The firm says Q1 consensus numbers on Paxlovid and Comirnaty appear too high, but if danuglipron data is disclosed on the day of Q1 results, danu moving into a large Phase 3 obesity program would negate a poor quarter, the analyst tells investors in a research note. UBS says it needs to see a stabilizing tail from the COVID business, continued growth in key assets, and execution on the pipeline to become more constructive on the name.
Goldman Sachs
Asad Haider
Strong Buy
to
Hold
Downgrades
$32 → $25
2025-04-08
Reason
Goldman Sachs
Asad Haider
Price Target
$32 → $25
2025-04-08
Downgrades
Strong Buy
to
Hold
Reason
Goldman Sachs downgraded Pfizer to Neutral from Buy with a price target of $25, down from $32, after assuming coverage of the name. The firm says that on the back of a challenging past two years which the company saw downward revisions around COVID related revenue expectations, it expects the shares to remain rangebound. Pfizer faces base business pressure, with greater clarity needed on acquisitions and pipeline levers required to necessitate a sustained stock re-rating, the analyst tells investors in a research note.
Guggenheim
Vamil Divan
Strong Buy
Reiterates
n/a
2025-03-18
Reason
Guggenheim
Vamil Divan
Price Target
n/a
2025-03-18
Reiterates
Strong Buy
Reason
Guggenheim
Vamil Divan
Strong Buy
Reiterates
n/a
2025-03-12
Reason
Guggenheim
Vamil Divan
Price Target
n/a
2025-03-12
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Pfizer Inc (PFE.N) is 8.92, compared to its 5-year average forward P/E of 12.59. For a more detailed relative valuation and DCF analysis to assess Pfizer Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair
5Y Average PE
12.59
Current PE
8.92
Overvalued PE
18.82
Undervalued PE
6.36
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair
5Y Average EV/EBITDA
9.80
Current EV/EBITDA
7.97
Overvalued EV/EBITDA
13.32
Undervalued EV/EBITDA
6.28
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued
5Y Average PS
3.02
Current PS
2.32
Overvalued PS
3.62
Undervalued PS
2.42
Financials
Annual
Quarterly
FY2025Q1
YoY :
-7.82%
13.72B
Total Revenue
FY2025Q1
YoY :
+4.39%
4.97B
Operating Profit
FY2025Q1
YoY :
-4.92%
2.97B
Net Income after Tax
FY2025Q1
YoY :
-5.45%
0.52
EPS - Diluted
FY2025Q1
YoY :
+358.81%
1.77B
Free Cash Flow
FY2025Q1
YoY :
+2.08%
72.27
Gross Profit Margin - %
FY2025Q1
YoY :
+96.71%
17.96
FCF Margin - %
FY2025Q1
YoY :
+3.14%
21.68
Net Margin - %
FY2025Q1
YoY :
+123.08%
6.96
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
64.8K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
147.7K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
1
499.1K
USD
Months
6-9
0
0.0
USD
Months
0-12
1
28.2K
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 1240.03% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
10.8M
Volume
13
6-9
Months
806.2K
Volume
18
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
5
78.2K
Volume
Months
6-9
17
21.8M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
16.0K
USD
2
3-6
Months
186.0K
USD
11
6-9
Months
32.0K
USD
4
0-12
Months
64.5K
USD
5
Bought
0-3
4
81.0K
USD
Months
3-6
9
145.5K
USD
Months
6-9
1
8.0K
USD
Months
0-12
2
65.0K
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
64.8K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
147.7K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
1
499.1K
USD
Months
6-9
0
0.0
USD
Months
0-12
1
28.2K
USD
Months
PFE News & Events
Events Timeline
2025-07-25 (ET)
2025-07-25
05:23:37
New
Pfizer, BioNTech get CHMP opinion for COVID-19 vaccine marketing authorization

2025-07-24 (ET)
2025-07-24
07:14:54
Study on Pfizer's 'Depo-Provera' shows increased brain tumor risk

2025-07-24
06:52:29
Pfizer completes licensing agreement with 3SBio

Sign Up For More Events
Sign Up For More Events
News
9.0
06:30 AMNewsfilterPfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
8.0
06:00 AMNASDAQ.COMWarren Buffett Owns 10 High-Yield Dividend Stocks. Here's the Best of the Bunch.
9.0
06:00 AMNASDAQ.COMPfizer, BioNTech Receive Positive CHMP Opinion For LP.8.1-adapted COVID-19 Vaccine
Sign Up For More News
People Also Watch

ABBV
AbbVie Inc
190.830
USD
+0.15%

TSM
Taiwan Semiconductor Manufacturing Co Ltd
241.600
USD
+0.53%

BAC
Bank of America Corp
48.390
USD
+0.52%

ACN
Accenture PLC
281.710
USD
-1.51%

ADBE
Adobe Inc
371.690
USD
-0.21%

PEP
PepsiCo Inc
144.510
USD
-0.79%

TMO
Thermo Fisher Scientific Inc
475.030
USD
+1.78%

MCD
McDonald's Corp
294.480
USD
-1.22%

KO
Coca-Cola Co
69.100
USD
-0.09%

CMCSA
Comcast Corp
35.370
USD
-1.17%
FAQ

What is Pfizer Inc (PFE) stock price today?
The current price of PFE is 25.35 USD — it has decreased -0.04 % in the last trading day.

What is Pfizer Inc (PFE)'s business?

What is the price predicton of PFE Stock?

What is Pfizer Inc (PFE)'s revenue for the last quarter?

What is Pfizer Inc (PFE)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Pfizer Inc (PFE)'s fundamentals?

How many employees does Pfizer Inc (PFE). have?
